But scientists say the experimental drug might be even more versatile, providing a new tool acomplia rimonabant to help people stop abusing drugs and alcohol, too. The percentage of patients with 10 percent or more acomplia rimonabant weight loss was significantly greater in the 20-mg group (27. 4 percent) acomplia rimonabant than the placebo group (7.
3 percent) but not in the 5-mg Acomplia rimonabant group (10. 1 percent). Acomplia rimonabant deangelis, editor of The Journal of the American Medical Association. Sanofi plans to launch Acomplia first in the UK, Germany, Ireland and Scandinavia.
New data indicate that obese adults who lose weight during a year of taking rimonabant and dieting keep the weight off during the following year, if they continue the regimen. But most of my patients actually enjoy the weight-loss process, because they feel stronger, acomplia rimonabant uplifted and more energetic. The most common adverse reactions were nausea, acomplia rimonabant dizziness, and upper respiratory tract infections. Rimonabant is the first of a new class of drugs that block certain receptors on brain and fat cells acomplia rimonabant belonging to the endocannabinoid (EC) system. Weight will just melt away, and fat accumulating around the waist and abdomen will be the first to go. I'm underwhelmed by the results so far. Rimonabant blocks a protein in brain cells that allows cannabis, the active ingredient in marijuana, to work. Acomplia pill fell 0. 8% from their acomplia rimonabant baseline value of 7. Acomplia rimonabant 9 %, as compared to a 0. 3% in the Acomplia rimonabant placebo group. Participants were excluded if they had a history of surgical procedures for weight loss or of significant depression, were currently taking medications known acomplia rimonabant to influence body weight, or intended to change their smoking status during the study period.
Sanofi's head of research and development, Grard Le Fur, said at the company's annual general meeting in Paris last week that he expects to get US approval by the end of the year. If they are heavy acomplia rimonabant drinkers, they will no longer crave alcohol. In studies of more than 6,600 people, the still-experimental drug helped people lose and maintain a weight loss of 19 pounds over two years while people on a placebo pill maintained only a 5-pound weight loss. George Kunos of the institute. Last month, Sanofi-Aventis announced first-half acomplia rimonabant results for a two-year, Phase III study of Acomplia in 13,000 patients. The idea of blocking these receptors worked in animals.